ArticleMicrosystems & nanoengineering2026
Hybrid additive manufacturing-based assembly of sacrificial isomalt scaffolds and gas exchange membranes for microfluidic artificial lung development.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preterm neonates are susceptible to respiratory distress syndrome (RDS) due to their underdeveloped lungs and require mechanical ventilation. Microfluidic blood oxygenators (MBOs) are a suitable alternative due to their small priming volume and their potential to reduce iatrogenic effects of ventilation. Current MBOs use lithographic fabrication that limits their manufacturability due to scalability and integration issues. Additive-manufacturing has been recently explored to overcome fabrication challenges, but has its own limitations in realizing scalable thin-membrane devices with high degree of channel patency. This work presents a new hybrid additive-manufacturing strategy for artificial lungs, by combining extrusion printing of sacrificial isomalt scaffolds with spin-coating of thin polydimethylsiloxane membranes. It eliminates the use of synthetic polymers or toxic solvents, yielding complete channel patency and biocompatibility. Using this scalable process, oxygenators with 11 alternating blood/gas layers separated by thin (121 µm) membranes were manufactured, achieving complete channel patency and a 0% rejection rate. In vitro evaluation showed reduced form-factor while achieving a high oxygen-transfer efficiency of 184 mL O
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.